Particularly in cancer, both molecules trigger adaptive immunity by recruiting immune cells, such as DCs, CD8+ T, and NK cells, into the tumor microenvironment, orchestrating Th1-type responses, complemented by the activation of highly effective cytotoxic effectors. The gene discussed is CD8A; the disease is neoplasm.